Publications by authors named "H J Ribaudo"
Background: Risk estimation is an essential component of cardiovascular disease prevention among people with HIV. We aimed to characterise how well atherosclerotic cardiovascular disease (ASCVD) risk scores used in clinical guidelines perform among people with HIV globally.
Methods: In this prospective cohort study leveraging REPRIEVE data, we included participants aged 40-75 years, with low-to-moderate traditional cardiovascular risk, not taking statin therapy.
Importance: In a mechanistic substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) randomized clinical trial, pitavastatin reduced noncalcified plaque (NCP) volume, but specific protein and gene pathways contributing to changes in coronary plaque remain unknown.
Objective: To use targeted discovery proteomics and transcriptomics approaches to interrogate biological pathways beyond low-density lipoprotein cholesterol (LDL-C), relating statin outcomes to reduce NCP volume and promote plaque stabilization among people with HIV (PWH).
Design, Setting, And Participants: This was a post hoc analysis of the double-blind, placebo-controlled, REPRIEVE randomized clinical trial.
Article Synopsis
- A study on the effects of statin therapy in people living with HIV (PWH) found that while it did not reduce the overall incidence of COVID-19, it may lower the risk of severe cases of COVID-19 before vaccination.
- The study analyzed data from 6,905 PWH and included variables such as age, gender, and race, showing that a majority had received COVID-19 vaccinations by the end of the study period.
- Statin therapy demonstrated a potential protective effect against serious COVID-19 cases, as evidenced by a hazard ratio of 0.75, but the results were inconclusive due to fewer cases than expected.
Article Synopsis
- REPRIEVE was a study that looked at how a medication called pitavastatin affects people with HIV and their risk of getting diabetes.
- The study included over 7,700 participants aged 40 to 75 who didn't have diabetes at the start.
- It found that people with more diabetes risk factors had a greater chance of developing diabetes, especially in places like South Asia.
Background: People with HIV-1 often have chronic inflammation leading to severe non-AIDS morbidity and mortality. The AIDS Clinical Trials Group Study A5314 sought to lower inflammation with low-dose methotrexate (LDMTX). The primary study outcomes were reported previously but here we present the impact of LDMTX on multiple measures of HIV-1 persistence.
View Article and Find Full Text PDF